FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065262979> ?p ?o ?g. }

• W2065262979 endingPage "888" @default.
• W2065262979 startingPage "881" @default.
• W2065262979 abstract "Background and objectives The two largest studies of mammalian target of rapamycin inhibitor treatment of autosomal dominant polycystic kidney disease (ADPKD) demonstrated no clear benefit on the primary endpoint of total kidney volume (TKV) or on eGFR. The present study evaluated two levels of rapamycin on the 12-month change in 125I-iothalamate GFR (iGFR) as the primary endpoint and TKV secondarily. Design, setting, participants, & measurements In a 12-month open-label pilot study, 30 adult patients with ADPKD were randomly assigned to low-dose (LD) rapamycin (rapamycin trough blood level, 2–5 ng/ml) (LD group, n=10), standard-dose (STD) rapamycin trough level (>5–8 ng/ml) (STD group, n=10), or standard care (SC group, n=10). They were evaluated with iGFR and noncontrast computed tomography. Results Change in iGFR at 12 months was significantly higher in the LD group (7.7±12.5 ml/min per 1.73 m2; n=9) than in the SC group (−11.2±9.1 ml/min per 1.73 m2; n=9) (LD versus SC: P<0.01). Change in iGFR at 12 months in the STD group (1.6±12.1 ml/min per 1.73 m2; n=8) was not significantly greater than that in the SC group (P=0.07), but it was in the combined treatment groups (LD+STD versus SC: P<0.01). Neither eGFR calculated by the CKD-Epidemiology Collaboration equation nor TKV (secondary endpoint) changed significantly from baseline to 12 months in any of the groups. On the basis of results of the mixed model, during the study, patients in the LD group had significantly lower trough blood levels of rapamycin (mean range±SD, 2.40±0.64 to 2.90±1.20 ng/ml) compared with those in the STD group (3.93±2.27 to 5.77±1.06 ng/ml) (P<0.01). Conclusion Patients with ADPKD receiving LD rapamycin demonstrated a significant increase in iGFR compared with those receiving standard care, without a significant effect on TKV after 12 months." @default.
• W2065262979 created "2016-06-24" @default.
• W2065262979 creator A5021944743 @default.
• W2065262979 creator A5036352911 @default.
• W2065262979 creator A5036536860 @default.
• W2065262979 creator A5059281770 @default.
• W2065262979 creator A5089157947 @default.
• W2065262979 date "2014-05-01" @default.
• W2065262979 modified "2023-10-07" @default.
• W2065262979 title "Low-Dose Rapamycin (Sirolimus) Effects in Autosomal Dominant Polycystic Kidney Disease" @default.
• W2065262979 cites W1550480781 @default.
• W2065262979 cites W1922782512 @default.
• W2065262979 cites W1924478590 @default.
• W2065262979 cites W1969449470 @default.
• W2065262979 cites W1983698019 @default.
• W2065262979 cites W1999095798 @default.
• W2065262979 cites W2018348216 @default.
• W2065262979 cites W2039044525 @default.
• W2065262979 cites W2053094829 @default.
• W2065262979 cites W2055919784 @default.
• W2065262979 cites W2060701084 @default.
• W2065262979 cites W2072100331 @default.
• W2065262979 cites W2072565259 @default.
• W2065262979 cites W2082060108 @default.
• W2065262979 cites W2088811685 @default.
• W2065262979 cites W2092906589 @default.
• W2065262979 cites W2096538221 @default.
• W2065262979 cites W2099652907 @default.
• W2065262979 cites W2100150669 @default.
• W2065262979 cites W2100483988 @default.
• W2065262979 cites W2100704215 @default.
• W2065262979 cites W2100978818 @default.
• W2065262979 cites W2110452525 @default.
• W2065262979 cites W2111820685 @default.
• W2065262979 cites W2119353448 @default.
• W2065262979 cites W2124283941 @default.
• W2065262979 cites W2131285944 @default.
• W2065262979 cites W2132018948 @default.
• W2065262979 cites W2132029812 @default.
• W2065262979 cites W2135563347 @default.
• W2065262979 cites W2141331673 @default.
• W2065262979 cites W2142574531 @default.
• W2065262979 cites W2143108257 @default.
• W2065262979 cites W2143990369 @default.
• W2065262979 cites W2146420434 @default.
• W2065262979 cites W2147221492 @default.
• W2065262979 cites W2147825900 @default.
• W2065262979 cites W2152198679 @default.
• W2065262979 cites W2154820433 @default.
• W2065262979 cites W2155965977 @default.
• W2065262979 cites W2158613256 @default.
• W2065262979 cites W2159693983 @default.
• W2065262979 cites W2166945866 @default.
• W2065262979 doi "https://doi.org/10.2215/cjn.02650313" @default.
• W2065262979 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4011437" @default.
• W2065262979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24721888" @default.
• W2065262979 hasPublicationYear "2014" @default.
• W2065262979 type Work @default.
• W2065262979 sameAs 2065262979 @default.
• W2065262979 citedByCount "52" @default.
• W2065262979 countsByYear W20652629792014 @default.
• W2065262979 countsByYear W20652629792015 @default.
• W2065262979 countsByYear W20652629792016 @default.
• W2065262979 countsByYear W20652629792017 @default.
• W2065262979 countsByYear W20652629792018 @default.
• W2065262979 countsByYear W20652629792019 @default.
• W2065262979 countsByYear W20652629792020 @default.
• W2065262979 countsByYear W20652629792021 @default.
• W2065262979 countsByYear W20652629792022 @default.
• W2065262979 countsByYear W20652629792023 @default.
• W2065262979 crossrefType "journal-article" @default.
• W2065262979 hasAuthorship W2065262979A5021944743 @default.
• W2065262979 hasAuthorship W2065262979A5036352911 @default.
• W2065262979 hasAuthorship W2065262979A5036536860 @default.
• W2065262979 hasAuthorship W2065262979A5059281770 @default.
• W2065262979 hasAuthorship W2065262979A5089157947 @default.
• W2065262979 hasBestOaLocation W20652629791 @default.
• W2065262979 hasConcept C126322002 @default.
• W2065262979 hasConcept C126894567 @default.
• W2065262979 hasConcept C134018914 @default.
• W2065262979 hasConcept C159641895 @default.
• W2065262979 hasConcept C203092338 @default.
• W2065262979 hasConcept C2776266639 @default.
• W2065262979 hasConcept C2777921159 @default.
• W2065262979 hasConcept C2780091579 @default.
• W2065262979 hasConcept C2909675724 @default.
• W2065262979 hasConcept C2911091166 @default.
• W2065262979 hasConcept C31785415 @default.
• W2065262979 hasConcept C535046627 @default.
• W2065262979 hasConcept C71924100 @default.
• W2065262979 hasConceptScore W2065262979C126322002 @default.
• W2065262979 hasConceptScore W2065262979C126894567 @default.
• W2065262979 hasConceptScore W2065262979C134018914 @default.
• W2065262979 hasConceptScore W2065262979C159641895 @default.
• W2065262979 hasConceptScore W2065262979C203092338 @default.
• W2065262979 hasConceptScore W2065262979C2776266639 @default.
• W2065262979 hasConceptScore W2065262979C2777921159 @default.
• W2065262979 hasConceptScore W2065262979C2780091579 @default.

• next